Headlines and summaries are written by AI. How it works
Moderna and Merck said on Thursday, 22 October, that their personalized mRNA vaccine cut the risk of melanoma death or recurrence by 42% against standard treatment. Full data is due at the ESMO congress in Madrid on Saturday, 24 October, after part of the results leaked online.